AstraZeneca (NYSE: AZN) today announced plans to conduct the EUCLID study, a global clinical trial involving 11,500 patients with peripheral artery disease (PAD), a condition affecting approximately 27 million people in Europe and North America. 1 PAD patients are at high risk of myocardial infarction (MI), strokes, and other health complications. EUCLID is designed to evaluate cardiovascular (CV) event rate and safety in PAD patients. Ticagrelor is currently not approved for the treatment of patients with PAD.
“The global burden of PAD is such that it necessitates further research of additional treatment options that may further reduce the risk of atherothrombotic CV events and CV death,” said William Hiatt, MD, Professor of Medicine, Division of Cardiology, University of Colorado School of Medicine. “The EUCLID study is an exciting clinical trial, as it may provide further clinical evidence regarding the role oral antiplatelets can play in reducing risk for patients with PAD.”
EUCLID is a randomized, double-blind, parallel group, multi-center study evaluating the efficacy of ticagrelor (monotherapy) compared to clopidogrel (monotherapy) in reducing the primary endpoint – a composite of CV death, MI or ischemic stroke – in patients with PAD.
In the EUCLID study, symptomatic PAD patients who are 50 years of age or older will be randomized to receive either ticagrelor 90 mg twice daily or clopidogrel 75 mg once daily. Now that plans to initiate the study have been finalized, the EUCLID steering committee will begin the process of recruiting study investigators, clinical centers, and eventually patients. Dr. Hiatt is the principal investigator for the EUCLID study, which is being conducted in partnership with the Duke Clinical Research Institute, an academic research organization affiliated with the Duke University School of Medicine, and CPC Clinical Research, an academic research organization affiliate of the University of Colorado.Ticagrelor Clinical Program The EUCLID study ( Examining Use of ti Cagre Lor In pa D) is part of the PARTHENON program, an AstraZeneca-funded comprehensive, long-term and evolving global research initiative designed to address unanswered questions in atherothrombotic disease, and to investigate the impact of ticagrelor on CV events and death. The current PARTHENON program is designed to include more than 51,000 patients worldwide. “Despite therapeutic advances, cardiovascular disease remains the number one cause of death worldwide,” said Judith Hsia, MD, Executive Director Clinical Research, AstraZeneca. “The PARTHENON program is part of our commitment to understand and advance treatments for cardiovascular diseases in an effort to improve patient health. The benefit of ticagrelor on CV thrombotic events, including CV mortality, observed in patients who have had an ACS event supports continued study in other areas of cardiovascular disease.”
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV